Document and Entity Information
Document and Entity Information - shares | 3 Months Ended | |
Mar. 31, 2021 | May 11, 2021 | |
Cover [Abstract] | ||
Entity Registrant Name | My Size, Inc. | |
Entity Central Index Key | 0001211805 | |
Document Type | 10-Q | |
Document Period End Date | Mar. 31, 2021 | |
Amendment Flag | false | |
Current Fiscal Year End Date | --12-31 | |
Entity Current Reporting Status | Yes | |
Entity Interactive Data Current | Yes | |
Entity Filer Category | Non-accelerated Filer | |
Entity Small Business | true | |
Entity Emerging Growth Company | false | |
Entity Shell Company | false | |
Entity Common Stock, Shares Outstanding | 12,538,327 | |
Document Fiscal Period Focus | Q1 | |
Document Fiscal Year Focus | 2021 |
Condensed Consolidated Interim
Condensed Consolidated Interim Balance Sheets (Unaudited) - USD ($) $ in Thousands | Mar. 31, 2021 | Dec. 31, 2020 |
Current Assets: | ||
Cash and cash equivalents | $ 5,756 | $ 1,689 |
Restricted cash | 82 | 85 |
Restricted deposit | 185 | 184 |
Accounts receivable | 27 | 28 |
Other receivables and prepaid expenses | 331 | 482 |
Total current assets | 6,381 | 2,468 |
Property and equipment, net | 116 | 128 |
Right-of-use asset | 837 | 911 |
Investment in marketable securities | 108 | 59 |
Total non-current assets | 1,061 | 1,098 |
Total assets | 7,442 | 3,566 |
Current liabilities: | ||
Operating lease liability | 123 | 129 |
Trade payables | 304 | 381 |
Accounts payable | 386 | 400 |
Derivatives | 7 | 1 |
Total current liabilities | 820 | 911 |
Operating lease liability | 529 | 579 |
Total non-current liabilities | 529 | 579 |
Total liabilities | 1,349 | 1,490 |
COMMITMENTS AND CONTINGENCIES | ||
Stockholders' equity: | ||
Stock Capital - Common stock of $ 0.001 par value - Authorized: 100,000,000 shares; Issued and outstanding: 12,145,547 and 7,232,836 as of March 31, 2021 and December 31, 2020, respectively | 12 | 7 |
Additional paid-in capital | 42,671 | 37,164 |
Accumulated other comprehensive loss | (462) | (424) |
Accumulated deficit | (36,128) | (34,671) |
Total stockholders' equity | 6,093 | 2,076 |
Total liabilities and stockholders' equity | $ 7,442 | $ 3,566 |
Condensed Consolidated Interi_2
Condensed Consolidated Interim Balance Sheets (Parenthetical) - $ / shares | Mar. 31, 2021 | Dec. 31, 2020 |
Statement of Financial Position [Abstract] | ||
Common stock, par value | $ 0.001 | $ 0.001 |
Common stock, shares authorized | 100,000,000 | 100,000,000 |
Common stock, shares issued | 12,145,547 | 7,232,836 |
Common stock, shares outstanding | 12,145,547 | 7,232,836 |
Condensed Consolidated Interi_3
Condensed Consolidated Interim Statements of Comprehensive Loss (Unaudited) - USD ($) $ in Thousands | 3 Months Ended | |
Mar. 31, 2021 | Mar. 31, 2020 | |
Income Statement [Abstract] | ||
Revenues | $ 27 | $ 30 |
Cost of revenues | (1) | |
Gross profit | 27 | 29 |
Operating expenses | ||
Research and development | (373) | (348) |
Sales and marketing | (546) | (625) |
General and administrative | (624) | (516) |
Total operating expenses | (1,543) | (1,489) |
Operating loss | (1,516) | (1,460) |
Financial income, net | 59 | 1 |
Net loss | (1,457) | (1,459) |
Other comprehensive loss: | ||
Foreign currency translation differences | (38) | (1) |
Total comprehensive loss | $ (1,495) | $ (1,460) |
Basic and diluted loss per share | $ (0.16) | $ (0.58) |
Basic and diluted weighted average number of shares outstanding | 9,166,601 | 2,504,530 |
Condensed Consolidated Interi_4
Condensed Consolidated Interim Statements of Changes in Stockholders' Equity - USD ($) $ in Thousands | Common Stock [Member] | Additional Paid-In Capital [Member] | Accumulated Other Comprehensive Loss [Member] | Accumulated Deficit [Member] | Total |
Balance at Dec. 31, 2019 | $ 2 | $ 30,102 | $ (539) | $ (28,514) | $ 1,051 |
Balance, shares at Dec. 31, 2019 | 2,085,900 | ||||
Stock-based compensation related to options granted to employees and consultants | 70 | 70 | |||
Issuance of shares, net of issuance cost | $ 1 | 1,693 | 1,694 | ||
Issuance of shares, net of issuance cost, shares | 514,801 | ||||
Liability reclassified to equity | 328 | 328 | |||
Total comprehensive loss | (1) | (1,459) | (1,460) | ||
Balance at Mar. 31, 2020 | $ 3 | 32,193 | (540) | (29,973) | 1,683 |
Balance, shares at Mar. 31, 2020 | 2,600,701 | ||||
Balance at Dec. 31, 2020 | $ 7 | 37,164 | (424) | (34,671) | 2,076 |
Balance, shares at Dec. 31, 2020 | 7,232,836 | ||||
Stock-based compensation related to options granted to employees and consultants | 143 | 143 | |||
Issuance of shares, net of issuance cost | $ 4 | 4,568 | 4,572 | ||
Issuance of shares, net of issuance cost, shares | 4,187,711 | ||||
Exercise of warrants | $ 1 | 796 | 797 | ||
Exercise of warrants, shares | 725,000 | ||||
Total comprehensive loss | (38) | (1,457) | (1,495) | ||
Balance at Mar. 31, 2021 | $ 12 | $ 42,671 | $ (462) | $ (36,128) | $ 6,093 |
Balance, shares at Mar. 31, 2021 | 12,145,547 |
Condensed Consolidated Interi_5
Condensed Consolidated Interim Statements of Changes in Stockholders' Equity (Parenthetical) - USD ($) $ in Thousands | 3 Months Ended | |
Mar. 31, 2021 | Mar. 31, 2020 | |
Statement of Stockholders' Equity [Abstract] | ||
Issuance cost, net | $ 736 | $ 358 |
Condensed Consolidated Interi_6
Condensed Consolidated Interim Statements of Cash Flows (Unaudited) - USD ($) $ in Thousands | 3 Months Ended | |
Mar. 31, 2021 | Mar. 31, 2020 | |
Cash flows from operating activities: | ||
Net loss | $ (1,457) | $ (1,459) |
Adjustments to reconcile net loss to net cash used in operating activities: | ||
Depreciation | 10 | 9 |
Amortization of operating lease right-of-use asset | 11 | 11 |
Revaluation of warrants and derivatives | 6 | (2) |
Revaluation of investment in marketable securities | (49) | (12) |
Stock based compensation | 143 | 70 |
Decrease in accounts receivables | 1 | 2 |
Decrease in other receivables and prepaid expenses | 149 | 95 |
Decrease in trade payable | (76) | (164) |
(Decrease) Increase in accounts payable | (9) | 14 |
Net cash used in operating activities | (1,271) | (1,436) |
Cash flows from investing activities: | ||
Investment in right-of-use asset | (25) | |
Purchase of property and equipment | (3) | (2) |
Net cash used in investing activities | (3) | (27) |
Cash flows from financing activities: | ||
Proceeds from issuance of shares, net of issuance costs | 4,572 | 1,694 |
Proceeds from Exercise of warrants | 797 | |
Net cash provided by financing activities | 5,369 | 1,694 |
Effect of exchange rate fluctuations on cash and cash equivalents | (31) | (6) |
Increase in cash, cash equivalents and restricted cash | 4,064 | 225 |
Cash, cash equivalents and restricted cash at the beginning of the period | 1,774 | 1,466 |
Cash, cash equivalents and restricted cash at the end of the period | $ 5,838 | $ 1,691 |
General
General | 3 Months Ended |
Mar. 31, 2021 | |
Organization, Consolidation and Presentation of Financial Statements [Abstract] | |
General | Note 1 - General a. My Size, Inc. is developing unique measurement technologies based on algorithms with applications in a variety of areas, from the apparel e-commerce market, to the courier services market and to the Do It Yourself smartphone and tablet apps market. The technology is driven by proprietary algorithms which are able to calculate and record measurements in a variety of novel ways. The Company has three subsidiaries, My Size Israel 2014 Ltd. and Topspin Medical (Israel) Ltd., both of which are incorporated in Israel and My Size LLC which was incorporated in Russian Federation. References to the Company include the subsidiaries unless the context indicates otherwise. b. During the three month period ended March 31, 2021, the Company has incurred significant losses and negative cash flows from operations and has an accumulated deficit of $36,128. The Company has financed its operations mainly through fundraising from various investors. The Company’s management expects that the Company will continue to generate losses and negative cash flows from operations for the foreseeable future. Based on the projected cash flows and cash balances as of March 31, 2021, management is of the opinion that its existing cash will be sufficient to fund operations until the end of March 2022. As a result, there is substantial doubt about the Company’s ability to continue as a going concern. Management’s plans include the continued commercialization of the Company’s products and securing sufficient financing through the sale of additional equity securities, debt or capital inflows from strategic partnerships. Additional funds may not be available when the Company needs them, on terms that are acceptable to it, or at all. If the Company is unsuccessful in commercializing its products and securing sufficient financing, it may need to cease operations. The financial statements include no adjustments for measurement or presentation of assets and liabilities, which may be required should the Company fail to operate as a going concern. |
Significant Accounting Policies
Significant Accounting Policies | 3 Months Ended |
Mar. 31, 2021 | |
Accounting Policies [Abstract] | |
Significant Accounting Policies | Note 2 - Significant Accounting Policies a. Unaudited condensed consolidated financial statements: The accompanying unaudited condensed consolidated interim financial statements included herein have been prepared by the Company in accordance with the rules and regulations of the United States Securities and Exchange Commission (“SEC”). The unaudited condensed consolidated financial statements are comprised of the financial statements of the Company. In management’s opinion, the interim financial data presented includes all adjustments necessary for a fair presentation. All intercompany accounts and transactions have been eliminated. Certain information required by U.S. generally accepted accounting principles (“GAAP”) has been condensed or omitted in accordance with rules and regulations of the SEC. Operating results for the three months ended March 31, 2021 are not necessarily indicative of the results that may be expected for any future period or for the year ending December 31, 2021. These unaudited condensed consolidated financial statements should be read in conjunction with the Company’s audited consolidated financial statements and the notes thereto for the year ended December 31, 2020. b. Use of estimates: The preparation of consolidated financial statements in conformity with GAAP requires us to make estimates and assumptions that affect the amounts reported and disclosed in the financial statements and the accompanying notes. Actual results could differ materially from these estimates. |
Financial Instruments
Financial Instruments | 3 Months Ended |
Mar. 31, 2021 | |
Investments, All Other Investments [Abstract] | |
Financial Instruments | Note 3 - Financial Instruments Fair value of financial instruments: Accounting Standards Codification (“ASC”) 820, Fair Value Measurements and Disclosures, relating to fair value measurements, defines fair value and established a framework for measuring fair value. ASC 820 fair value hierarchy distinguishes between market participant assumptions developed based on market data obtained from sources independent of the reporting entity and the reporting entity’s own assumptions about market participant assumptions developed based on the best information available in the circumstances. ASC 820 defines fair value as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date, essentially an exit price. In addition, the fair value of assets and liabilities should include consideration of non-performance risk, which for the liabilities described below includes the Company’s own credit risk. In accordance with ASC 820 when measuring the fair value, an entity shall take into account the characteristics of the asset or liability if a market participant would take those characteristics into account when pricing the asset or liability at the measurement date. Such characteristics include, for example: a. The condition and location of the asset. b. Restrictions, if any, on the sale or the use of the asset. As a basis for considering such assumptions, ASC 820 establishes a three-tier value hierarchy, which prioritizes the inputs used in the valuation methodologies in measuring fair value: Level 1 - Valuations based on quoted prices in active markets for identical assets that the Company has the ability to access. Valuation adjustments and block discounts are not applied to Level 1 instruments. Since valuations are based on quoted prices that are readily and regularly available in an active market, valuation of these products does not entail a significant degree of judgment. Level 2 - Valuations based on one or more quoted prices in markets that are not active or for which all significant inputs are observable, either directly or indirectly. Level 3 - Valuations based on inputs that are unobservable and significant to the overall fair value measurement. The expected volatility of the share prices reflects the assumption that the historical volatility of the share prices is reasonably indicative of expected future trends. The carrying amounts of cash and cash equivalents, accounts receivable, other receivables, trade payables and accounts payable approximate their fair value due to the short-term maturities of such instruments. The Company holds share certificates in iMine Corporation (“iMine”) formerly known as Diamante Minerals, Inc., a publicly-traded company on the OTCQB. Due to sales restrictions on the sale of the iMine share, the fair value of the shares was measured on the basis of the quoted market price for an otherwise identical unrestricted equity instrument of the same issuer that trades in a public market, adjusted to reflect the effect of the sales restrictions and is therefore, ranked as Level 2 assets. March 31, 2021 Fair value hierarchy Level 1 Level 2 Level 3 Financial assets Investment in marketable securities (*) - 108 - March 31, 2021 Fair value hierarchy Level 1 Level 2 Level 3 Financial liabilities Derivatives - 7 - December 31, 2020 Fair value hierarchy Level 1 Level 2 Level 3 Financial assets Investment in marketable securities (*) - 59 - (*) For the three month period ended March 31, 2021 and 2020, the recognized gain (based on quoted market prices with a discount due to security restrictions on iMine shares) of the marketable securities was $49 and $33, respectively. |
Stock Based Compensation
Stock Based Compensation | 3 Months Ended |
Mar. 31, 2021 | |
Share-based Payment Arrangement [Abstract] | |
Stock Based Compensation | Note 4 - Stock Based Compensation The stock-based expense equity awards recognized in the financial statements for services received is related to Research and Development, Sales and Marketing and General and Administrative expenses as shown in the following table: Three months ended March 31, 2021 2020 Stock-based compensation expense - Research and Development 61 20 Stock-based compensation expense - Sales and Marketing 25 22 Stock-based compensation expense - General and Administrative 57 28 143 70 Options issued to consultants: During the three month period ended March 31, 2021, the Company did not grant any options to consultants, no such options were exercised and options to purchase 1,000 shares expired. The total stock option compensation expense during the three month period ended March 31, 2021 and 2020 which was recorded under sales and marketing was $7 and $4, respectively and under general and administrative was $0 and $6, respectively. Stock Option Plan for Employees: In March 2017, the Company adopted the My Size, Inc. 2017 Equity Incentive Plan (the “2017 Employee Plan”) pursuant to which the Company’s Board of Directors may grant stock options to officers and key employees. The total number of options which may be granted to directors, officers, employees under this plan, was initially limited to 200,000 shares of common stock. Stock options can be granted with an exercise price equal to or less than the stock’s fair market value at the grant date. As further described below, in August 2020, the Company’s shareholders approved an increase in the number of shares available for issuance under the Plan to 1,450,000. On May 25, 2020, the compensation committee of the Board of Directors of the Company reduced the exercise price of outstanding options of employees and directors of the Company for the purchase of an aggregate of 140,237 shares of common stock of the Company (with exercise prices ranging between $18.15 and $9.15) to $1.04 per share, which was the closing price for the Company’s common stock on May 22, 2020, and extended the term of the foregoing options for an additional one year from the original date of expiration. The incremental compensation cost resulting from the repricing was $53, and the expenses during three months ended 31, 2021 and 2020 were $1 and $0, respectively. On August 10, 2020, the Company’s shareholders approved an increase in the shares available for issuance under the 2017 Employee Plan from 200,000 to 1,450,000 shares. As a result and pursuant to approval of the Company’s compensation committee that was contingent on the foregoing shareholder approval, the number of shares available for issuance under the Company’s 2017 Consultant Incentive Plan was reduced from 466,667 to 216,667 shares. During the three month period ended March 31, 2021, the Company did not grant any stock options under the 2017 Employee Plan, no such options were exercised and options to purchase 21,610 shares of common stock expired. The total stock option compensation expense during the three month period ended March 31, 2021 and 2020 which was recorded was $136 and $60, respectively. |
Contingencies and Commitments
Contingencies and Commitments | 3 Months Ended |
Mar. 31, 2021 | |
Commitments and Contingencies Disclosure [Abstract] | |
Contingencies and Commitments | Note 5 - Contingencies and Commitments a. On August 7, 2018, the Company commenced an action against North Empire LLC (“North Empire”) in the Supreme Court of the State of New York, County of New York for breach of a Securities Purchase Agreement (the “Agreement”) in which it is seeking damages in an amount to be determined at trial, but in no event less than $616,000. On August 2, 2018, North Empire filed a Summons with Notice against the Company, also in the same Court, in which they allege damages in an amount of $11.4 million arising from an alleged breach of the Agreement. On September 6, 2018 North Empire filed a Notice of Discontinuance of the action it had filed on August 2, 2018. On September 27, 2018, North Empire filed an answer and asserted counterclaims in the action commenced by the Company against them, alleging that the Company failed to deliver stock certificates to North Empire causing damage to North Empire in the amount of $10,958,589. North Empire also filed a third-party complaint against the Company’s CEO and now former Chairman of the Board asserting similar claims against them in their individual capacities. On October 17, 2018, the Company filed a reply to North Empire’s counterclaims. On November 15, 2018, the Company’s CEO and now former Chairman of the Board filed a motion to dismiss North Empire’s third-party complaint. On January 6, 2020, the Court granted the motion and dismissed the third-party complaint. Discovery has been completed and both parties have filed motions for summary judgment in connection with the claims and counterclaims. The Company believes it is more likely than not that the counterclaims will be denied. |
Significant Events During the R
Significant Events During the Reporting Period | 3 Months Ended |
Mar. 31, 2021 | |
Significant Events During Reporting Period | |
Significant Events During the Reporting Period | Note 6 - Significant Events During the Reporting Period a. On January 8, 2021, the Company conducted a public offering of its securities pursuant to which it issued 1,569,179 shares of its common stock for gross proceeds of $2,008. The net proceeds to the Company from the offering were approximately $1,700, after deducting placement agent’s fees and other estimated offering expenses payable by the Company. b. In January and February 2021, a holder of warrants exercised warrants to purchase 725,000 ordinary shares of the Company in exchange for $797. c. On March 25, 2021, the Company conducted a public offering of its shares of common stock pursuant to which it issued 2,618,532 shares of its common stock for gross proceeds of $3,300. The net proceeds to the Company from the offering were approximately $2,872, after deducting placement agent’s fees and other estimated offering expenses payable by the Company. d. In late 2019, a novel strain of COVID-19, also known as coronavirus, was reported in Wuhan, China. While initially the outbreak was largely concentrated in China, it has now spread to Israel and the United States, and infections have been reported globally. Many countries around the world, including in Israel, have from time to time significant governmental measures being implemented to control the spread of the virus, including temporary closure of businesses, severe restrictions on travel and the movement of people, and other material limitations on the conduct of business. These measures have resulted in work stoppages and other disruptions. The Company has implemented remote working and work place protocols for its employees in accordance with government requirements. In addition, while the Company has seen an increased demand for MySizeID, the COVID-19 pandemic has had a particularly adverse impact on the retail industry and this has resulted in an adverse impact on the Company’s marketing and sales activities. For example, the Company has three ongoing pilots with international retailers that have been halted, the Company is unable to participate physically in industry conferences, its ability to meet with potential customers is limited and in certain instances sales processes have been delayed or cancelled. The extent to which COVID-19 continues to impact the Company’s operations will depend on future developments, which are highly uncertain and cannot be predicted with confidence, including the duration and severity of the outbreak, and the actions that may be required to contain COVID-19 or treat its impact. |
Events Subsequent to the Balanc
Events Subsequent to the Balance Sheet Date | 3 Months Ended |
Mar. 31, 2021 | |
Subsequent Events [Abstract] | |
Events Subsequent to the balance sheet date | Note 7 - Events Subsequent to the balance sheet date a. On May 7, 2021, the Company closed on the sale of an additional 392,780 shares of the Company’s common stock in connection with the full exercise of the underwriter’s overallotment option granted in the Company’s March 2021 public offering. These additional shares were sold to the underwriter at a public offering price of $1.26 per share, resulting in additional net proceeds to the Company, net of the underwriting discount, of approximately $460. |
Significant Accounting Polici_2
Significant Accounting Policies (Policies) | 3 Months Ended |
Mar. 31, 2021 | |
Accounting Policies [Abstract] | |
Unaudited Condensed Consolidated Financial Statements | a. Unaudited condensed consolidated financial statements: The accompanying unaudited condensed consolidated interim financial statements included herein have been prepared by the Company in accordance with the rules and regulations of the United States Securities and Exchange Commission (“SEC”). The unaudited condensed consolidated financial statements are comprised of the financial statements of the Company. In management’s opinion, the interim financial data presented includes all adjustments necessary for a fair presentation. All intercompany accounts and transactions have been eliminated. Certain information required by U.S. generally accepted accounting principles (“GAAP”) has been condensed or omitted in accordance with rules and regulations of the SEC. Operating results for the three months ended March 31, 2021 are not necessarily indicative of the results that may be expected for any future period or for the year ending December 31, 2021. These unaudited condensed consolidated financial statements should be read in conjunction with the Company’s audited consolidated financial statements and the notes thereto for the year ended December 31, 2020. |
Use of Estimates | b. Use of estimates: The preparation of consolidated financial statements in conformity with GAAP requires us to make estimates and assumptions that affect the amounts reported and disclosed in the financial statements and the accompanying notes. Actual results could differ materially from these estimates. |
Financial Instruments (Tables)
Financial Instruments (Tables) | 3 Months Ended |
Mar. 31, 2021 | |
Investments, All Other Investments [Abstract] | |
Schedule of Fair value of Financial Assets and Liabilities | March 31, 2021 Fair value hierarchy Level 1 Level 2 Level 3 Financial assets Investment in marketable securities (*) - 108 - March 31, 2021 Fair value hierarchy Level 1 Level 2 Level 3 Financial liabilities Derivatives - 7 - December 31, 2020 Fair value hierarchy Level 1 Level 2 Level 3 Financial assets Investment in marketable securities (*) - 59 - (*) For the three month period ended March 31, 2021 and 2020, the recognized gain (based on quoted market prices with a discount due to security restrictions on iMine shares) of the marketable securities was $49 and $33, respectively. |
Stock Based Compensation (Table
Stock Based Compensation (Tables) | 3 Months Ended |
Mar. 31, 2021 | |
Share-based Payment Arrangement [Abstract] | |
Schedule of Stock Based Expenses | The stock-based expense equity awards recognized in the financial statements for services received is related to Research and Development, Sales and Marketing and General and Administrative expenses as shown in the following table: Three months ended March 31, 2021 2020 Stock-based compensation expense - Research and Development 61 20 Stock-based compensation expense - Sales and Marketing 25 22 Stock-based compensation expense - General and Administrative 57 28 143 70 |
General (Details Narrative)
General (Details Narrative) - USD ($) $ in Thousands | Mar. 31, 2021 | Dec. 31, 2020 |
Organization, Consolidation and Presentation of Financial Statements [Abstract] | ||
Accumulated deficit | $ (36,128) | $ (34,671) |
Financial Instruments - Schedul
Financial Instruments - Schedule of Fair Value of Financial Assets and Liabilities (Details) - USD ($) $ in Thousands | Mar. 31, 2021 | Dec. 31, 2020 | |
Fair Value, Inputs, Level 1 [Member] | |||
Investment in marketable securities | [1] | ||
Derivatives | |||
Fair Value, Inputs, Level 2 [Member] | |||
Investment in marketable securities | [1] | 108 | 59 |
Derivatives | 7 | ||
Fair Value, Inputs, Level 3 [Member] | |||
Investment in marketable securities | [1] | ||
Derivatives | |||
[1] | For the three month period ended March 31, 2021 and 2020, the recognized gain (based on quoted market prices with a discount due to security restrictions on iMine shares) of the marketable securities was $49 and $33, respectively. |
Financial Instruments - Sched_2
Financial Instruments - Schedule of Fair Value of Financial Assets and Liabilities (Details) (Parenthetical) - USD ($) $ in Thousands | 3 Months Ended | |
Mar. 31, 2021 | Mar. 31, 2020 | |
Investments, All Other Investments [Abstract] | ||
Gain on marketable securities | $ 49 | $ 33 |
Stock Based Compensation (Detai
Stock Based Compensation (Details Narrative) - USD ($) $ / shares in Units, $ in Thousands | May 25, 2020 | Mar. 31, 2017 | Mar. 31, 2021 | Mar. 31, 2020 | Aug. 10, 2020 |
Number of options expired | 1,000 | ||||
Stock option compensation | $ 143 | $ 70 | |||
2017 Employee Plan [Member] | |||||
Number of options expired | 21,610 | ||||
Number of shares available for issuance | 200,000 | 1,450,000 | |||
Options exercised | |||||
2017 Employee Plan [Member] | Common Stock [Member] | |||||
Number of options granted | 140,237 | 200,000 | |||
Exercise price | $ 1.04 | ||||
Incremental compensation cost | $ 53 | ||||
Incremental compensation expenses | $ 1 | 0 | |||
2017 Employee Plan [Member] | Common Stock [Member] | Minimum [Member] | |||||
Exercise price | $ 18.15 | ||||
2017 Employee Plan [Member] | Common Stock [Member] | Maximum [Member] | |||||
Exercise price | $ 9.15 | ||||
2017 Consultant Incentive Plan [Member] | Minimum [Member] | |||||
Number of shares available for issuance | 466,667 | ||||
2017 Consultant Incentive Plan [Member] | Maximum [Member] | |||||
Number of shares available for issuance | 216,667 | ||||
Sales and Marketing [Member] | |||||
Stock option compensation expense | 7 | 4 | |||
Stock option compensation | 25 | 22 | |||
General and Administrative [Member] | |||||
Stock option compensation expense | 0 | 6 | |||
Stock option compensation | $ 57 | $ 28 |
Stock Based Compensation - Sche
Stock Based Compensation - Schedule of Stock Based Expenses (Details) - USD ($) $ in Thousands | 3 Months Ended | |
Mar. 31, 2021 | Mar. 31, 2020 | |
Stock-based compensation expense | $ 143 | $ 70 |
Research and Development [Member] | ||
Stock-based compensation expense | 61 | 20 |
Sales and Marketing [Member] | ||
Stock-based compensation expense | 25 | 22 |
General and Administrative [Member] | ||
Stock-based compensation expense | $ 57 | $ 28 |
Contingencies and Commitments (
Contingencies and Commitments (Details Narrative) - North Empire LLC [Member] - USD ($) | Sep. 27, 2018 | Aug. 07, 2018 | Aug. 02, 2018 |
Seeking damages amount | $ 10,958,589 | $ 11,400,000 | |
Securities Purchase Agreement [Member] | |||
Seeking damages amount | $ 616,000 |
Significant Events During the_2
Significant Events During the Reporting Period (Details Narrative) - USD ($) | Mar. 25, 2021 | Jan. 08, 2021 | Feb. 28, 2021 | Mar. 31, 2021 | Mar. 31, 2020 | Jan. 31, 2021 |
Proceeds from common stock | $ 4,572,000 | $ 1,694,000 | ||||
Exercise of warrants | 725,000 | 725,000 | ||||
Exchange of ordinary shares | $ 797 | |||||
Public Offering [Member] | ||||||
Number of common stock issued | 2,618,532 | 1,569,179 | ||||
Proceeds from common stock | $ 3,300 | $ 2,008 | ||||
Net proceeds from from offering | $ 2,872 | $ 1,700 |
Events Subsequent to the Bala_2
Events Subsequent to the Balance Sheet Date (Details Narrative) - Subsequent Event [Member] - Underwriters Overallotment Option [Member] | May 07, 2021USD ($)$ / sharesshares |
Number of sale for shares with exercise of option granted | shares | 392,780 |
Sale of stock, price per share | $ / shares | $ 1.26 |
Proceeds from public offering, net of underwriting discount | $ | $ 460 |